Drugs & Therapy Perspectives

, Volume 18, Issue 5, pp 16–20 | Cite as

Tumour necrosis factor-α blockers: increasing the options for managing rheumatoid arthritis

Disease Management
  • 14 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Keating GM, Jarvis B. Management of rheumatoid arthritis: defining the role of etanercept. Dis Manage Health Outcomes 2002; 10(1): 17–39CrossRefGoogle Scholar
  2. 2.
    Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66PubMedCrossRefGoogle Scholar
  3. 3.
    Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28: 1423–30PubMedGoogle Scholar
  4. 4.
    Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000 Jun; 59(6): 1341–59PubMedCrossRefGoogle Scholar
  5. 5.
    Richard-Miceli C, Dougados M. Tumour necrosis factorα blockers in rheumatoid arthritis. BioDrugs 2001; 15(4): 251–59PubMedCrossRefGoogle Scholar
  6. 6.
    British National Formulary. No 42. London: The Pharmaceutical Press, 2001 Sep: 485Google Scholar
  7. 7.
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor amonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9PubMedCrossRefGoogle Scholar
  8. 8.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93PubMedCrossRefGoogle Scholar
  9. 9.
    Spencer-Green G, Genovese M, Martin RW, et al. Etanercept versus methotrexate in early rheumatoid arthritis (ERA trial): two-year follow-up [abstract]. J Rheumatol 2001 Jul; 28 Suppl. 63: 106Google Scholar
  10. 10.
    Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled study. Arch Intern Med 1999; 130: 478–86Google Scholar
  11. 11.
    Weinblatt ME, Kremer JM, Bankhurst, AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9PubMedCrossRefGoogle Scholar
  12. 12.
    Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 738–45PubMedCrossRefGoogle Scholar
  13. 13.
    Infliximab (Remicade®): prescribing information. Malvern (PA): Centocor, 1999.Google Scholar
  14. 14.
    Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug-induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217Google Scholar
  15. 15.
    Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 699–702CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations